Use Impacts Women’s Emotional
THE CORPORATION Schering-Plough declared results recently terminated analysis, showing that not-consent with multifunction hormonal contraceptive has an observable effects in emotional well-being of the women, prompted requests about advice and has conducted to raised use to incidental contraception. The Results were presented in Madrid, Spain and were published more early this month in Contraceptions.
Cross-sectional, much centre the analysis was intended to value itself- described influence noncompliant behaviours amongst 26,250 current consumers, old 18 on 49, three united hormonal contraceptive methods, multifunction pill, patch of the skin and NUVARING(R) (etonogestrel/ethinyl estradiol vaginal ring), vaginal ring.
” Analysis included the questions about relations and psychological influence of the inconsistent use the contraceptive method when constant noncompliant behaviour, issue, which is weakly characterized in preceding study,” commented Dr Inaki Lete, Hospital Santiago Apostol, Vitoria-Gasteiz, Spain and leaden investigator. “These considerations will help the to accredit the womans to enlarge the consent with given contraceptive mode.”
The Analysis found that 71 percents of the consumers of the pill, 32 percents of the consumers of the patch and 21.6 percent of the recirculating consumers reported noncompliant behaviour. Between 10 and 20 percents of the womans reported that noncompliant behaviour with their current method negatively acted upon worker activity and their relationship with their partner, and beside 3 percents has missed the days of the work or schools. The more high percent of the consumers of the pill reported that they ‘were be worried or ‘frightened (68.8 percent and 22.6 percent accordingly) in contrast with woman, used patch of the skin (61.7 percent and 19 percents) or vaginal ring (58.3 percent and 16.4 percent).
In addition to influence of emotional well-being of the women, incomplete contraceptive use also had an economic sense depending on contraceptive method used. Beside 40 percents of the womans in all group named or visitted physician because of birth control of the method not-adherence. 14 percents of the consumers of the pill, 11 percents of the consumers of the patch and 6.3 percent of the recirculating consumers asked incidental contraception. 40 percents of the pill and consumers of the patch workable test to pregnancy in contrast with 29 percents of that use vaginal.
Finally, after terminate the questionnaire, 64.7 percent of the consumers of the pill that contraceptive pill, 61.7 percent of the consumers of the patch of the skin preferred the patch transdermal and 96.6 percent of the womans, used vaginal ring preferred the ring. The Bounded problems of the Consent were an most important reason provided for contraceptive change the method. The Similar percent of the womans in pill and group of the patch of the skin changed on vaginal ring (31.6 percent and 32.9 percent, accordingly) since amongst consumers vaginal only 1 percent changed in pill and 3 percents patch skins.
About analysis
Three month analysises were executed in clinic outpatient division to gynecologies and planning to families centre public and quotient of the institutions in Spain in 2006. In the general 458 physicians The Womens old 18 at 49 years, which were a current consumer of one of the methods and addressed to their physician for scheduled usual contraceptive visit were eligible, provided they give written and reported consent and were capable to understand and terminate the questionnaire of the analysis. Not-compliant behaviour was determined as loss or delays in current of the taking/ exhibits/introduction or removing the pill.
Kombenizon, 65 percents of the womans, taking part in analysis currently used the multifunction Pill, 23 percents vaginal ring and 12 percents patch skins. Amongst womans, who used their method for less than 18 months, 39.4 percent used Pill, 39.1 percent ring and 21.5 percent patch.
The Analysis also shown that following not-consent, majority of the women continued to use same contraceptive method, between 55 and 63 percents waited begin bleedings and beside 40 percents of the pill and consumers of the patch workable test to pregnancy in contrast with 29 percents of that use vaginal Besides, more high percent of the pill and consumers of the patch (43.9 percent and 39.7 percent accordingly) reported feelling relief at the beginning initially their withdrawal to haemorrhage than recirculating consumers (20.2 percent) (p<0.05). Kombenizon, 70 percents continued to have an active sexual life and 60 percents used additional contraceptive method.
The Protocol of the analysis was approved by Expert Committee in Contraceptions Spanish Society to Contraceptions. The Analysis was supported from Spanish Society of the Contraceptions gratis and Spain Organon.
About NUVARING
NUVARING - ne-biodegradable, flexible, transparent colourless on nearly colourless contraceptive vaginal to combinations. It Is Specified for prevention of pregnancy in woman, who are elected to use this product as method to contraceptions. Like spoken contraceptive, NUVARING very efficient if it is used as it is recommended on label.
Designed Organon, NUVARING was first licensed for use in USA in 2002. Safety and efficiency NUVARING, when is used in accordance with labeling the product, was well installed in clinical test and through commercial experience. There is more, than 1.5 million of the current consumers worldwide. In three greater clinical trials of 13 cycles of the use NUVARING, the factors to pregnancy were between one and two on 100 womans-years of the use.
NUVARING LAYS releasing unceasing low dose hormone, at the average count;calculate;list 0.120 mg. etonogestrel ( progestin) and 0.015 mg. ethinyl estradiol ( estrogen), per diem for twenty-one day periods of the use.
NUVARING HAS an external diameter 54 mm and cross-sectional diameter 4 mm. The Patients easy include and delete NUVARING using their finger to press the sides an together and carefully pop this in vagina. Exact positioning NUVARING within vagina not critical for product to work since NUVARING is not a barrier contraceptive and consequently not to can is wrong included. In introduction, NUVARING begins to release the firm flow a hormone and work to prevent pregnancy on monthly base.
To prevent pregnancy for full month, vaginal ring must be included according to instruction stated in labeling the product and left on place during three consequent weeks. This means that ring is removed three weeks later same weekday as it was included and aproximately around same time. NUVARING CAN be removed by seizure of the index finger under forward rim or understanding rim between subscripted and middle fingers and pulling this. After one-week interruption, during which haemorrhage withdrawal usually occurs, new ring is comprised of the same weekday as it was removed.
Important Safe Information
NUVARING(R), is not protected against infection HIV and other sexual sent diseases. Use to combinations spoken contraceptive is bound raised by risk several serious side effects, including blood clot, which can conduct to blow or heart attack. NUVARING(R), - not for womans with historian of these conditions or for womans with determined cancer or that, which can be pregnant. The Risk to get the blood, clot can be greater with type progestin in NUVARING(R) than with some other progestins in low dose on birth rate pill determined checking. This unknown if risk blood clot another with NUVARING use(R) than with use determined birth control pill. The Cigarette smoke enlarges the risk serious side effect, particularly in woman over 35; the women(woman)s who combination of the use hormonal contraceptive not is powerfully advised to smoke. Most general side effects gave NUVARING users(R) - a vaginal infections and irritation, vaginal secretion, headache, increase of the weight, and sickness.
